Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Jessica LimbergCaitlin E EganKatherine D GrayMandeep SinghZachary LoewensteinYanping YangMaria Cristina RiascosHala Al AsadiParima SafeSteve El EshakyHeng LiangTimothy M UllmannWeibin WangWei LiTuo ZhangJenny Zhaoying XiangDessislava StefanovaMoonsoo M JinRasa ZarnegarThomas J FaheyIrene M MinPublished in: Molecular cancer research : MCR (2023)
Dual inhibition of BRAF and JAK/STAT signaling pathway is a potential therapeutic treatment for anticancer activity and to overcome drug resistance to BRAFi in thyroid cancer.